BR0007187A - Hidróxi-matairresinol na prevenção contra o câncer - Google Patents

Hidróxi-matairresinol na prevenção contra o câncer

Info

Publication number
BR0007187A
BR0007187A BR0007187-0A BR0007187A BR0007187A BR 0007187 A BR0007187 A BR 0007187A BR 0007187 A BR0007187 A BR 0007187A BR 0007187 A BR0007187 A BR 0007187A
Authority
BR
Brazil
Prior art keywords
matairresinol
hydroxy
person
relates
administration
Prior art date
Application number
BR0007187-0A
Other languages
English (en)
Inventor
Markku Ahotupa
Christer Eckerman
Lauri Kangas
Sari Mokelo
Niina Saarinen
Risto Santti
Anni Worri
Original Assignee
Hormos Nutraceutical Oy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Nutraceutical Oy Ltd filed Critical Hormos Nutraceutical Oy Ltd
Publication of BR0007187A publication Critical patent/BR0007187A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"HIDRóXI-MATAIRRESINOL NA PREVENçAO CONTRA O CâNCER". A presente invenção refere-se a métodos para prevenção de cânceres, certas doenças não cancerosas dependentes de hormónios e/ou doenças cardiovasculares em uma pessoa, baseado na administração de hidróxi-matairresinol à dita pessoa. A invenção se refere também a um método para aumentar o nível de enterolactona ou outro metabólito de hidróxi-matairresinol no soro de uma pessoa, causando dessa forma a prevenção de um câncer ou de uma doença não bancerosa dependente de hormónio em uma pessoa, baseado na administração de hidróxi-matairresinol à dita pessoa. Além disso, a invenção se refere a preparações farmacêuticas, aditivos de alimentos e produtos alimentícios que compreendem hidróxi-matairresinol.
BR0007187-0A 1999-03-30 2000-03-09 Hidróxi-matairresinol na prevenção contra o câncer BR0007187A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/281,094 US6451849B1 (en) 1999-03-30 1999-03-30 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
PCT/FI2000/000181 WO2000059946A1 (en) 1999-03-30 2000-03-09 Hydroxymatairesinol in cancer prevention

Publications (1)

Publication Number Publication Date
BR0007187A true BR0007187A (pt) 2002-02-19

Family

ID=23075932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007187-0A BR0007187A (pt) 1999-03-30 2000-03-09 Hidróxi-matairresinol na prevenção contra o câncer

Country Status (25)

Country Link
US (2) US6451849B1 (pt)
EP (1) EP1165537B1 (pt)
JP (2) JP4852685B2 (pt)
KR (2) KR100741723B1 (pt)
CN (1) CN1146553C (pt)
AT (1) ATE231500T1 (pt)
AU (1) AU767691B2 (pt)
BG (1) BG65380B1 (pt)
BR (1) BR0007187A (pt)
CA (2) CA2371839C (pt)
CZ (2) CZ302730B6 (pt)
DE (1) DE60001271T2 (pt)
DK (1) DK1165537T3 (pt)
EE (1) EE200100507A (pt)
ES (1) ES2189738T3 (pt)
HK (1) HK1045992B (pt)
HU (1) HUP0200530A3 (pt)
MX (1) MXPA01009714A (pt)
NO (4) NO330135B1 (pt)
NZ (1) NZ512099A (pt)
PL (1) PL199892B1 (pt)
RU (1) RU2241453C2 (pt)
SK (2) SK287001B6 (pt)
WO (1) WO2000059946A1 (pt)
ZA (1) ZA200104440B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271257B1 (en) * 2000-04-17 2001-08-07 Hormos Nutraceutical Oy Ltd. Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
WO2002034277A1 (en) * 2000-10-23 2002-05-02 Council Of Scientific And Industrial Research Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
WO2003016883A1 (en) * 2001-08-16 2003-02-27 Analiza, Inc. A method of measuring solubility
ES2342713T3 (es) * 2001-11-12 2010-07-13 Analiza, Inc. Caracterizacion de moleculas.
FI111638B (fi) 2001-11-23 2003-08-29 Hormos Nutraceutical Oy Ltd Menetelmä hydroksimatairesinolin tuottamiseksi puusta
US7008666B2 (en) * 2001-11-26 2006-03-07 Hormos Nutraceutical Oy Ltd. Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
US20030144216A1 (en) * 2002-01-25 2003-07-31 Mikko Unkila Method for prevention of diseases in coeliac patients
EP1472206A1 (en) * 2002-02-05 2004-11-03 Hormos Medical Corporation Lignan derivatives
US7048960B2 (en) * 2002-03-22 2006-05-23 Glenn Roy Pizzey High lignan flaxseed product and product by process
FI20021184A (fi) 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
FR2851919A1 (fr) * 2003-03-03 2004-09-10 Lmd Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
US8099242B2 (en) 2003-06-12 2012-01-17 Analiza, Inc. Systems and methods for characterization of molecules
US7976877B2 (en) 2003-11-12 2011-07-12 Oy Arbonova Ab Use of knotwood extracts
FI116727B (sv) 2003-11-12 2006-02-15 Arbonova Ab Oy Ny användning för kvistnötsextrakt
WO2005063233A1 (ja) * 2003-12-26 2005-07-14 Tokyo University Of Agriculture And Technology Tlo Co., Ltd. 肝癌予防及び治療用組成物
CN1842327B (zh) * 2004-02-03 2011-05-11 株式会社红豆杉 将源于云南红豆杉的异紫杉脂素作为成分的骨质疏松症预防、治疗药
JP2008526819A (ja) * 2005-01-10 2008-07-24 ホルモス メディカル リミテッド エストロゲン欠乏に関連する症状を予防または改善するための組成物を製造するためのリグナンの使用
US7595078B2 (en) * 2005-03-15 2009-09-29 Glanbia Nutritionals Ireland Limited Methods of increasing flaxseed hull recovery and resultant flax products
CA2633654A1 (en) 2005-12-19 2008-01-10 Analiza, Inc. Systems and methods involving data patterns such as spectral biomarkers
DE102006008772A1 (de) * 2006-02-22 2007-08-23 Beiersdorf Ag Hydroxymatairesinol gegen trockene Haut
DE102006019044A1 (de) * 2006-04-25 2007-10-31 Merck Patent Gmbh Antioxidantien
FI20106293A0 (fi) * 2010-12-06 2010-12-06 Emilia Peuhu Uudet farmaseuttiset koostumukset
EP2517574B1 (de) 2011-04-29 2015-11-11 Symrise AG Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer
US10613087B2 (en) 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
RU2510268C1 (ru) * 2012-11-14 2014-03-27 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс" Средство для лечения эстрогензависимых опухолей
AU2015261470A1 (en) 2014-05-15 2016-10-27 Linnea S.A. Composition comprising 7-hydroxymatairesinol
US9678076B2 (en) 2014-06-24 2017-06-13 Analiza, Inc. Methods and devices for determining a disease state
CZ305794B6 (cs) * 2015-04-20 2016-03-16 Výzkumný ústav potravinářský Praha, v.v.i. Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě
US9669006B2 (en) 2015-07-28 2017-06-06 U.S. Nutraceuticals, LLC Composition and method to treat and alleviate symptoms of hot flashes in a female subject
CA3008075A1 (en) * 2015-12-09 2017-06-15 Oy Granula Ab Ltd The use of a composition for lowering cholesterol level in a mammal, a method for its preparation, a composition and a method for preparing food additive comprising said composition
IT201700050994A1 (it) 2017-05-11 2018-11-11 Linnea Sa Uso di una Composizione comprendente 7-Idrossimatairesinolo
CA3236536A1 (en) 2021-10-28 2023-05-04 Arnon Chait Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628228D0 (en) * 1986-11-26 1986-12-31 Inst Biolog Morya Dalnevostoch Composition inhibiting pathological addiction to alcohol
US4808674A (en) * 1987-08-24 1989-02-28 General Electric Company Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom
DE4317466A1 (de) 1993-05-26 1994-12-01 Degussa Verbessertes Verfahren zur Bleiche von Holzstoffen
DE69521525T2 (de) 1995-10-18 2002-04-25 Kanoldt Arzneimittel Gmbh Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
AU2100997A (en) 1996-03-08 1997-09-22 Energiser Plc Composition containing iso-flavonoids and lignans
US5846944A (en) 1996-04-04 1998-12-08 The University Of Saskatchewan Purified SDG as an antioxidant
JP2987365B1 (ja) * 1998-10-29 1999-12-06 かどや製油株式会社 抗酸化剤
WO2005063233A1 (ja) * 2003-12-26 2005-07-14 Tokyo University Of Agriculture And Technology Tlo Co., Ltd. 肝癌予防及び治療用組成物

Also Published As

Publication number Publication date
ZA200104440B (en) 2002-07-30
WO2000059946A8 (en) 2001-01-25
NO20111291L (no) 2001-09-25
NO332110B1 (no) 2012-06-25
BG105856A (en) 2002-04-30
HUP0200530A2 (hu) 2002-07-29
NO331188B1 (no) 2011-10-31
KR100741723B1 (ko) 2007-07-23
KR100741724B1 (ko) 2007-07-23
CN1345315A (zh) 2002-04-17
CZ302730B6 (cs) 2011-10-05
SK13262001A3 (sk) 2002-02-05
NO20014639L (no) 2001-09-25
NZ512099A (en) 2004-01-30
HK1045992B (zh) 2005-02-25
ATE231500T1 (de) 2003-02-15
JP2011052024A (ja) 2011-03-17
WO2000059946A1 (en) 2000-10-12
BG65380B1 (bg) 2008-05-30
KR20010108434A (ko) 2001-12-07
NO332251B1 (no) 2012-08-06
KR20070027770A (ko) 2007-03-09
EP1165537A1 (en) 2002-01-02
US20010016590A1 (en) 2001-08-23
CA2371839C (en) 2011-10-04
PL199892B1 (pl) 2008-11-28
ES2189738T3 (es) 2003-07-16
DK1165537T3 (da) 2003-05-12
DE60001271D1 (de) 2003-02-27
SK287001B6 (sk) 2009-09-07
PL350367A1 (en) 2002-12-02
US6451849B1 (en) 2002-09-17
CZ20013486A3 (cs) 2002-02-13
SK287749B6 (sk) 2011-08-04
NO20014639D0 (no) 2001-09-25
CA2371839A1 (en) 2000-10-12
AU3169200A (en) 2000-10-23
DE60001271T2 (de) 2003-07-31
HUP0200530A3 (en) 2002-10-28
CZ301725B6 (cs) 2010-06-02
EE200100507A (et) 2002-12-16
CA2650297C (en) 2012-05-15
NO330135B1 (no) 2011-02-21
EP1165537B1 (en) 2003-01-22
NO20101067L (no) 2001-09-25
JP2002541158A (ja) 2002-12-03
CA2650297A1 (en) 2000-10-12
NO20101701L (no) 2001-09-25
HK1045992A1 (en) 2002-12-20
MXPA01009714A (es) 2003-06-24
CN1146553C (zh) 2004-04-21
AU767691B2 (en) 2003-11-20
JP4852685B2 (ja) 2012-01-11
RU2241453C2 (ru) 2004-12-10

Similar Documents

Publication Publication Date Title
BR0007187A (pt) Hidróxi-matairresinol na prevenção contra o câncer
Clarkson Soy, soy phytoestrogens and cardiovascular disease
Gupta et al. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis
Lilja et al. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
BR9815302A (pt) Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular
MA27285A1 (fr) COMBINAISON D'AZELASTINE ET DE STEROiDES
Elalamy et al. Long‐term treatment of cancer‐associated thrombosis: the choice of the optimal anticoagulant
Giannelli et al. EGFR and VEGFR as potential target for biological therapies in HCC cells
BR0110837A (pt) Quimioterapia de combinação
Sibaud et al. T-DM1-related telangiectasias: a potential role in secondary bleeding events
BR0014979A (pt) Composição hormonal e sua utilização
NO20050216L (no) Steroidkonjugater samt fremstilling og anvendelse derav
Depypere et al. Inhibition of tamoxifen's therapeutic benefit by tangeretin in mammary cancer
Di Lorenzo et al. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer
Sonpavde et al. New approaches in hormone refractory prostate cancer
TNSN04101A1 (fr) ASSOCIATIONS PHARMACEUTIQUES D'UN AGONISTE DE RECEPTEUR D'ADENOSINE A2a ET D'UN AGONISTE DE RECEPTEUR ADRENERGIQUE B2
Breijo-Márquez Misuse of the Drug Acenocoumarol in a Population of 250 Inhabitants with Non-valvular Atrial Fibrillation Assessed in a Region of Southeaster of Spain
GB et al. Bullous Lichen Planus of Oral Mucosa: A Case Report
Tameire et al. Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
Detsyk et al. The clinical picture and diagnosis of the Gilbert-Meylengraht syndrome
PUCHE et al. Changes in Plasma Aspirin and Cholinesterase Activity in Patients with Myocardial Infarction or Stroke

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/365 (2006.01), A23L 33/105 (2016.01)